Cargando…
MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation
SIMPLE SUMMARY: Neuroblastoma is a pediatric tumor originating from the sympathetic nervous system responsible for 10–15% of all childhood cancer deaths. Half of all neuroblastoma patients present with high-risk disease, of which nearly 50% relapse and die of their disease. In addition, standard the...
Autores principales: | De Wyn, Jolien, Zimmerman, Mark W., Weichert-Leahey, Nina, Nunes, Carolina, Cheung, Belamy B., Abraham, Brian J., Beckers, Anneleen, Volders, Pieter-Jan, Decaesteker, Bieke, Carter, Daniel R., Look, Alfred Thomas, De Preter, Katleen, Van Loocke, Wouter, Marshall, Glenn M., Durbin, Adam D., Speleman, Frank, Durinck, Kaat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508013/ https://www.ncbi.nlm.nih.gov/pubmed/34638267 http://dx.doi.org/10.3390/cancers13194783 |
Ejemplares similares
-
MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014) -
From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma
por: Decaesteker, Bieke, et al.
Publicado: (2021) -
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
por: Decaesteker, Bieke, et al.
Publicado: (2018) -
In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2018) -
Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2019)